Loading…
Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose
The initial dose of bendamustine, an alkylating agent used in treating indolent lymphoma (iNHL) and mantle cell lymphoma, is variable in clinical practice. 134 patients treated with bendamustine and rituximab were evaluated for starting dosage, patient characteristics, toxicities, and clinical outco...
Saved in:
| Published in: | Leukemia & lymphoma 2017-07, Vol.58 (7), p.1589-1597 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c468t-345ab8816fa26439369218d19d330bd923db37c6fc974c7295b31933fe51aefc3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c468t-345ab8816fa26439369218d19d330bd923db37c6fc974c7295b31933fe51aefc3 |
| container_end_page | 1597 |
| container_issue | 7 |
| container_start_page | 1589 |
| container_title | Leukemia & lymphoma |
| container_volume | 58 |
| creator | Bond, David A. Huang, Ying Ruppert, Amy S. Walker, Alison R. Dotson, Emily K. Roddy, Julianna Blum, Kristie A. Christian, Beth A. |
| description | The initial dose of bendamustine, an alkylating agent used in treating indolent lymphoma (iNHL) and mantle cell lymphoma, is variable in clinical practice. 134 patients treated with bendamustine and rituximab were evaluated for starting dosage, patient characteristics, toxicities, and clinical outcome. The starting dosage ranged from 50 to 90 mg/m
2
. Lower starting dosage ( |
| doi_str_mv | 10.1080/10428194.2016.1253835 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_10428194_2016_1253835</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>27838951</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-345ab8816fa26439369218d19d330bd923db37c6fc974c7295b31933fe51aefc3</originalsourceid><addsrcrecordid>eNp9kdtqFDEYx4NYbK0-gpIXmDXH2eRGlFJboSAUvQ6ZHLbRTLIk2bb7Bj52M25b9EYIJPA_fEl-ALzDaIWRQB8wYkRgyVYE4XGFCaeC8hfgBCMiB8IQfbmcGRkW0zF4XetPhBCXI3kFjslaUCE5PgG_r10ruW6daeHWQZ103NdQYfZwcsnqeVdbSItgYQltdx9mPcFddTCkvmyOLrU_6qxTiw4aFyNMOQ2X2W5-dVPcz9ubPGs46eoszEsstKAjrE2XXr6BNlf3Bhx5Hat7-7ifgh9fzr-fXQ5X3y6-nn2-GgwbRRso43oSAo9ek5FRSUdJsLBYWkrRZCWhdqJrM3oj18ysieQTxZJS7zjWzht6Cj4eere7aXbW9OsXHdW29IeVvco6qH-VFG7UJt8qzqTkhPYCfigw_d9qcf45i5Fa0KgnNGpBox7R9Nz7vwc_p55YdMOngyEkn8us73KJVjW9j7n4opMJVdH_z3gArCeh8A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Bond, David A. ; Huang, Ying ; Ruppert, Amy S. ; Walker, Alison R. ; Dotson, Emily K. ; Roddy, Julianna ; Blum, Kristie A. ; Christian, Beth A.</creator><creatorcontrib>Bond, David A. ; Huang, Ying ; Ruppert, Amy S. ; Walker, Alison R. ; Dotson, Emily K. ; Roddy, Julianna ; Blum, Kristie A. ; Christian, Beth A.</creatorcontrib><description>The initial dose of bendamustine, an alkylating agent used in treating indolent lymphoma (iNHL) and mantle cell lymphoma, is variable in clinical practice. 134 patients treated with bendamustine and rituximab were evaluated for starting dosage, patient characteristics, toxicities, and clinical outcome. The starting dosage ranged from 50 to 90 mg/m
2
. Lower starting dosage (<90 mg/m
2
) was associated with relapsed disease, increased age and worse performance status (PS), histologic subtype other than follicular lymphoma, baseline renal impairment, and cytopenias. No significant difference was observed in toxicities between patients treated with 90 mg/m
2
compared with lower doses. The starting dose of 90 mg/m
2
was associated with a higher complete response rate (56% vs. 29%) and longer progression free survival (PFS) (39.5 months vs. 19.7 months). However, in a multivariable model, the higher starting dose was not associated with longer PFS in those with similar age, histology, PS, and number of prior therapies.</description><identifier>ISSN: 1042-8194</identifier><identifier>EISSN: 1029-2403</identifier><identifier>DOI: 10.1080/10428194.2016.1253835</identifier><identifier>PMID: 27838951</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bendamustine ; Bendamustine Hydrochloride - administration & dosage ; Female ; Humans ; immunotherapeutic approaches ; Kaplan-Meier Estimate ; lymphoma and Hodgkin disease ; Lymphoma, Mantle-Cell - diagnosis ; Lymphoma, Mantle-Cell - drug therapy ; Lymphoma, Mantle-Cell - mortality ; Male ; Middle Aged ; Neoplasm Staging ; Odds Ratio ; Proportional Hazards Models ; Retrospective Studies ; Rituximab - administration & dosage ; Treatment Outcome ; Young Adult</subject><ispartof>Leukemia & lymphoma, 2017-07, Vol.58 (7), p.1589-1597</ispartof><rights>2016 Informa UK Limited, trading as Taylor & Francis Group 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-345ab8816fa26439369218d19d330bd923db37c6fc974c7295b31933fe51aefc3</citedby><cites>FETCH-LOGICAL-c468t-345ab8816fa26439369218d19d330bd923db37c6fc974c7295b31933fe51aefc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27838951$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bond, David A.</creatorcontrib><creatorcontrib>Huang, Ying</creatorcontrib><creatorcontrib>Ruppert, Amy S.</creatorcontrib><creatorcontrib>Walker, Alison R.</creatorcontrib><creatorcontrib>Dotson, Emily K.</creatorcontrib><creatorcontrib>Roddy, Julianna</creatorcontrib><creatorcontrib>Blum, Kristie A.</creatorcontrib><creatorcontrib>Christian, Beth A.</creatorcontrib><title>Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose</title><title>Leukemia & lymphoma</title><addtitle>Leuk Lymphoma</addtitle><description>The initial dose of bendamustine, an alkylating agent used in treating indolent lymphoma (iNHL) and mantle cell lymphoma, is variable in clinical practice. 134 patients treated with bendamustine and rituximab were evaluated for starting dosage, patient characteristics, toxicities, and clinical outcome. The starting dosage ranged from 50 to 90 mg/m
2
. Lower starting dosage (<90 mg/m
2
) was associated with relapsed disease, increased age and worse performance status (PS), histologic subtype other than follicular lymphoma, baseline renal impairment, and cytopenias. No significant difference was observed in toxicities between patients treated with 90 mg/m
2
compared with lower doses. The starting dose of 90 mg/m
2
was associated with a higher complete response rate (56% vs. 29%) and longer progression free survival (PFS) (39.5 months vs. 19.7 months). However, in a multivariable model, the higher starting dose was not associated with longer PFS in those with similar age, histology, PS, and number of prior therapies.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bendamustine</subject><subject>Bendamustine Hydrochloride - administration & dosage</subject><subject>Female</subject><subject>Humans</subject><subject>immunotherapeutic approaches</subject><subject>Kaplan-Meier Estimate</subject><subject>lymphoma and Hodgkin disease</subject><subject>Lymphoma, Mantle-Cell - diagnosis</subject><subject>Lymphoma, Mantle-Cell - drug therapy</subject><subject>Lymphoma, Mantle-Cell - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Odds Ratio</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Rituximab - administration & dosage</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1042-8194</issn><issn>1029-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kdtqFDEYx4NYbK0-gpIXmDXH2eRGlFJboSAUvQ6ZHLbRTLIk2bb7Bj52M25b9EYIJPA_fEl-ALzDaIWRQB8wYkRgyVYE4XGFCaeC8hfgBCMiB8IQfbmcGRkW0zF4XetPhBCXI3kFjslaUCE5PgG_r10ruW6daeHWQZ103NdQYfZwcsnqeVdbSItgYQltdx9mPcFddTCkvmyOLrU_6qxTiw4aFyNMOQ2X2W5-dVPcz9ubPGs46eoszEsstKAjrE2XXr6BNlf3Bhx5Hat7-7ifgh9fzr-fXQ5X3y6-nn2-GgwbRRso43oSAo9ek5FRSUdJsLBYWkrRZCWhdqJrM3oj18ysieQTxZJS7zjWzht6Cj4eere7aXbW9OsXHdW29IeVvco6qH-VFG7UJt8qzqTkhPYCfigw_d9qcf45i5Fa0KgnNGpBox7R9Nz7vwc_p55YdMOngyEkn8us73KJVjW9j7n4opMJVdH_z3gArCeh8A</recordid><startdate>20170703</startdate><enddate>20170703</enddate><creator>Bond, David A.</creator><creator>Huang, Ying</creator><creator>Ruppert, Amy S.</creator><creator>Walker, Alison R.</creator><creator>Dotson, Emily K.</creator><creator>Roddy, Julianna</creator><creator>Blum, Kristie A.</creator><creator>Christian, Beth A.</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20170703</creationdate><title>Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose</title><author>Bond, David A. ; Huang, Ying ; Ruppert, Amy S. ; Walker, Alison R. ; Dotson, Emily K. ; Roddy, Julianna ; Blum, Kristie A. ; Christian, Beth A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-345ab8816fa26439369218d19d330bd923db37c6fc974c7295b31933fe51aefc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bendamustine</topic><topic>Bendamustine Hydrochloride - administration & dosage</topic><topic>Female</topic><topic>Humans</topic><topic>immunotherapeutic approaches</topic><topic>Kaplan-Meier Estimate</topic><topic>lymphoma and Hodgkin disease</topic><topic>Lymphoma, Mantle-Cell - diagnosis</topic><topic>Lymphoma, Mantle-Cell - drug therapy</topic><topic>Lymphoma, Mantle-Cell - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Odds Ratio</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Rituximab - administration & dosage</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bond, David A.</creatorcontrib><creatorcontrib>Huang, Ying</creatorcontrib><creatorcontrib>Ruppert, Amy S.</creatorcontrib><creatorcontrib>Walker, Alison R.</creatorcontrib><creatorcontrib>Dotson, Emily K.</creatorcontrib><creatorcontrib>Roddy, Julianna</creatorcontrib><creatorcontrib>Blum, Kristie A.</creatorcontrib><creatorcontrib>Christian, Beth A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Leukemia & lymphoma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bond, David A.</au><au>Huang, Ying</au><au>Ruppert, Amy S.</au><au>Walker, Alison R.</au><au>Dotson, Emily K.</au><au>Roddy, Julianna</au><au>Blum, Kristie A.</au><au>Christian, Beth A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose</atitle><jtitle>Leukemia & lymphoma</jtitle><addtitle>Leuk Lymphoma</addtitle><date>2017-07-03</date><risdate>2017</risdate><volume>58</volume><issue>7</issue><spage>1589</spage><epage>1597</epage><pages>1589-1597</pages><issn>1042-8194</issn><eissn>1029-2403</eissn><abstract>The initial dose of bendamustine, an alkylating agent used in treating indolent lymphoma (iNHL) and mantle cell lymphoma, is variable in clinical practice. 134 patients treated with bendamustine and rituximab were evaluated for starting dosage, patient characteristics, toxicities, and clinical outcome. The starting dosage ranged from 50 to 90 mg/m
2
. Lower starting dosage (<90 mg/m
2
) was associated with relapsed disease, increased age and worse performance status (PS), histologic subtype other than follicular lymphoma, baseline renal impairment, and cytopenias. No significant difference was observed in toxicities between patients treated with 90 mg/m
2
compared with lower doses. The starting dose of 90 mg/m
2
was associated with a higher complete response rate (56% vs. 29%) and longer progression free survival (PFS) (39.5 months vs. 19.7 months). However, in a multivariable model, the higher starting dose was not associated with longer PFS in those with similar age, histology, PS, and number of prior therapies.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>27838951</pmid><doi>10.1080/10428194.2016.1253835</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1042-8194 |
| ispartof | Leukemia & lymphoma, 2017-07, Vol.58 (7), p.1589-1597 |
| issn | 1042-8194 1029-2403 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_10428194_2016_1253835 |
| source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bendamustine Bendamustine Hydrochloride - administration & dosage Female Humans immunotherapeutic approaches Kaplan-Meier Estimate lymphoma and Hodgkin disease Lymphoma, Mantle-Cell - diagnosis Lymphoma, Mantle-Cell - drug therapy Lymphoma, Mantle-Cell - mortality Male Middle Aged Neoplasm Staging Odds Ratio Proportional Hazards Models Retrospective Studies Rituximab - administration & dosage Treatment Outcome Young Adult |
| title | Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T22%3A46%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retrospective%20analysis%20of%20bendamustine%20and%20rituximab%20use%20in%20indolent%20and%20mantle%20cell%20non-Hodgkin%20lymphoma%20based%20on%20initial%20starting%20dose&rft.jtitle=Leukemia%20&%20lymphoma&rft.au=Bond,%20David%20A.&rft.date=2017-07-03&rft.volume=58&rft.issue=7&rft.spage=1589&rft.epage=1597&rft.pages=1589-1597&rft.issn=1042-8194&rft.eissn=1029-2403&rft_id=info:doi/10.1080/10428194.2016.1253835&rft_dat=%3Cpubmed_cross%3E27838951%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c468t-345ab8816fa26439369218d19d330bd923db37c6fc974c7295b31933fe51aefc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/27838951&rfr_iscdi=true |